Search

Sarepta Therapeutics Inc

Closed

SectorHealthcare

22.36 -2.7

Overview

Share price change

24h

Current

Min

21.96

Max

22.86

Key metrics

By Trading Economics

Income

-4.9M

326M

Sales

-330M

401M

P/E

Sector Avg

42.919

56.659

EPS

0.42

Profit margin

81.263

Employees

835

EBITDA

-345M

30M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-0.48% downside

Dividends

By Acuity

Next Earnings

2 lis 2026

Market Stats

By TradingEconomics

Market Cap

545M

2.2B

Previous open

25.06

Previous close

22.36

News Sentiment

By Acuity

100%

0%

327 / 339 Ranking in Healthcare

Sarepta Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 wrz 2026, 23:36 UTC

Sarepta Therapeutics Inc. shares traded roughly flat after market hours, while major indices gained amid easing interest rate concerns.

2 wrz 2026, 20:02 UTC

Social Media

Sarepta Therapeutics shares are higher as investor interest grows ahead of clinical data for treatments targeting muscular dystrophy, despite a pullback from session highs.

1 wrz 2026, 20:09 UTC

Sarepta Therapeutics Inc shares are higher today, supported by gains in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

31 sie 2026, 20:07 UTC

Sarepta Therapeutics shares are higher amid broader market concerns over inflation, with no specific company news identified to explain the movement.

28 sie 2026, 19:51 UTC

News

Sarepta Therapeutics reported a 34% revenue decline to $401.3 million for Q2 2026, as execution risks weigh on shares during the current session.

27 sie 2026, 23:02 UTC

Sarepta Therapeutics shares declined in after-market trading amid a broader market pullback, despite earlier gains during the session. No specific news was identified.

26 sie 2026, 20:08 UTC

Sarepta Therapeutics Inc shares are higher today amid broader market gains, despite no specific company news identified. Recent inflation data may be influencing market trends.

25 sie 2026, 19:26 UTC

Sarepta Therapeutics Inc. shares are higher today amid notable volatility, despite no specific news to explain the movement. Broader market conditions support higher valuations.

24 sie 2026, 20:06 UTC

News

Sarepta Therapeutics shares decline amid investigation into potential fiduciary breaches and safety concerns regarding its gene therapy, Elevidys.

21 sie 2026, 19:26 UTC

Sarepta Therapeutics Inc is trading lower today, with no specific news identified for the decline. Broader market trends show a rebound in U.S. stocks.

20 sie 2026, 23:56 UTC

Sarepta Therapeutics Inc. shares traded roughly flat in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

19 sie 2026, 23:11 UTC

Sarepta Therapeutics shares are lower in after-market hours amid a broader decline in the Biotechnology sub-sector, showing unusual volatility during the session.

18 sie 2026, 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, retracing gains amid broader market weakness linked to rising sovereign bond yields and inflation concerns.

17 sie 2026, 19:36 UTC

Sarepta Therapeutics Inc shares are higher, continuing their advance since Friday's close and trading above the 20-day moving average. No specific news was identified.

14 sie 2026, 19:36 UTC

Sarepta Therapeutics shares are lower today amid broader market sentiment following a reported decline in retail sales for July. No specific company news was identified.

13 sie 2026, 19:36 UTC

Sarepta Therapeutics shares are trading roughly flat, with no specific news identified. The price remains significantly above the 20-day moving average.

12 sie 2026, 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, continuing a decline since Wednesday's close, with no specific news identified to explain the drop.

11 sie 2026, 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement amid broader market focus on inflation data.

10 sie 2026, 23:52 UTC

Sarepta Therapeutics shares are lower in after-market hours, with no specific news identified for the decline amid broader market sentiment influenced by labor report data.

7 sie 2026, 19:36 UTC

News

Sarepta Therapeutics reports Q2 2026 revenue of $401.3 million, down from $611.1 million a year earlier, with shares trading lower during the session.

6 sie 2026, 20:03 UTC

Social Media
News

Sarepta Therapeutics shares are higher following strong Q2 results, with adjusted EPS of $0.64 and revenue of $401.3 million exceeding estimates.

5 sie 2026, 23:11 UTC

News
Social Media

Sarepta Therapeutics reported Q2 adjusted EPS of $0.64, exceeding estimates. Revenue reached $401.3 million, driving shares higher in after-market trading.

4 sie 2026, 19:31 UTC

Sarepta Therapeutics is higher today, benefiting from strong tech stock performance and increased U.S. manufacturing activity, despite pulling back earlier in the session.

3 sie 2026, 20:03 UTC

Sarepta Therapeutics Inc shares are higher today, reflecting broader market strength. The S&P 500 and Nasdaq 100 have also advanced during the session.

30 lip 2026, 19:58 UTC

Sarepta Therapeutics Inc shares are lower today, with no specific news driving the decline. The stock is trading significantly below its 20-day moving average.

29 lip 2026, 22:06 UTC

News

Sarepta Therapeutics granted inducement stock options to CEO Dr. Michael Severino, with shares trading higher in after-market hours following the announcement.

28 lip 2026, 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours amid a broader market decline, with no specific news identified to explain the movement.

27 lip 2026, 23:16 UTC

Social Media

Sarepta Therapeutics appoints Michael Severino as CEO, effective July 28. Shares are higher in after-market trading following the leadership change.

21 lip 2026, 17:51 UTC

Sarepta Therapeutics shares are lower today, pulling back from earlier session highs amid no specific news. The stock remains near the lower end of its one-month range.

Peer Comparison

Price change

Sarepta Therapeutics Inc Forecast

Price Target

By TipRanks

-0.48% downside

12 Months Forecast

Average 22.88 USD  -0.48%

High 38 USD

Low 5 USD

Based on 17 Wall Street analysts offering 12 month price targets forSarepta Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

17 ratings

5

Buy

8

Hold

4

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat